32693-80-4

Upstream product

• 178113-56-9 L-2-hydroxy-3-methylbutanoic acid allyl ester 
• 13516-17-1 benzyloxycarbonyl-L-valyl-L-α-hydroxyisovaleric acid t-butyl ester 
• 3519-30-0 L-α-hydroxyisovaleric acid t-butyl ester 
• 1149-26-4 (S)-N-(benzyloxycarbonyl)valine 

Downstream Products

• 105087-53-4 benzyloxycarbonyl-L-valyl-L-α-hydroxyisovaleryl-L-valyl-L-α-hydroxyisovaleric acid 
• 125760-11-4 benzyloxycarbonyl-L-valyl-L-α-hydroxyisovaleryl-L-valyl-L-α-hydroxyisovaleryl-L-valyl-L-α-hydroxyisovaleryl-L-valyl-L-α-hydroxyisovaleric acid pentafluorophenyl ester 
• 174757-67-6 benzyloxycarbonyl-L-valyl-L-α-hydroxyisovaleryl-L-valyl-L-α-hydroxyisovaleric acid t-butyl ester 

Relevant academic research and scientific papers

Total synthesis of proposed structure of coibamide A, a highly N- and O-methylated cytotoxic marine cyclodepsipeptide

Total synthesis of the originally proposed structure of coibamide A, a highly N- and O-methylated cytotoxic marine cyclodepsipeptide, has been accomplished by using a [(4+1)+3+3]-peptide fragment-coupling strategy and careful examination and optimization

Non-nucleoside reverse transcriptase inhibitors

Non-nucleoside reverse transcriptase inhibitors of formula (P-1) wherein: Ar1 is an unsaturated, optionally substituted, mono or bicyclic ring structure comprising 0 to 3 hetero atoms selected from S, O and N; Ar2 is an aromatic, optionally substituted, monocyclic ring structure comprising at least one nitrogen hetero atom and zero to two further hetero atoms selected from S, O and N; R4 and R5 are independently H or C3-C8 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C5 alkoxy, C1-C4 alkanoyloxy, C1-C4 alkylthio, amino, carboxy, carbamoyl, cyano, halo, hydroxy, aminomethyl, hydroxymethyl, carboxymethyl, or halo substituted C1-C6 alkyl mercapto, nitro; or R4 and RS join to form a 3-6 membered, optionally substituted ring structure; R6 is 0 or S; Rx is the residue of a natural or unnatural amino acid; and L* is a linker moiety which is ether-, carbonate- or ester-bound to the adjacent oxygen and ester linked to Rx; and pharmaceutically acceptable salts thereof are anti-HIV agents with favourable pharmacokinetic properties.

Applications of pentafluorophenylester coupling in the synthesis of cyclodepsipeptides related to valinomycins

A number of strategies of synthesis of cyclic depsipeptides are examined including cyclisation protocols based on pentafluorophenyl esters. The alternatives of amine protection as benzyloxycarbonyl or t-butoxycarbonyl derivatives are examined and optimum